A detailed history of Pnc Financial Services Group, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 79,429 shares of VRTX stock, worth $35.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
79,429
Previous 75,160 5.68%
Holding current value
$35.8 Million
Previous $35.2 Million 4.86%
% of portfolio
0.02%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$460.0 - $505.78 $1.96 Million - $2.16 Million
4,269 Added 5.68%
79,429 $36.9 Million
Q2 2024

Aug 09, 2024

SELL
$392.81 - $485.53 $1.88 Million - $2.33 Million
-4,794 Reduced 6.0%
75,160 $35.2 Million
Q1 2024

May 10, 2024

BUY
$407.69 - $446.08 $1.33 Million - $1.45 Million
3,258 Added 4.25%
79,954 $33.4 Million
Q4 2023

Feb 09, 2024

BUY
$343.0 - $410.68 $833,833 - $998,363
2,431 Added 3.27%
76,696 $31.2 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $531,957 - $570,149
1,573 Added 2.16%
74,265 $25.8 Million
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $1.41 Million - $1.58 Million
4,480 Added 6.57%
72,692 $25.6 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $584,303 - $666,555
-2,063 Reduced 2.94%
68,212 $21.5 Million
Q4 2022

Feb 10, 2023

SELL
$285.76 - $321.48 $665,249 - $748,405
-2,328 Reduced 3.21%
70,275 $20.3 Million
Q3 2022

Nov 10, 2022

BUY
$273.83 - $305.53 $341,739 - $381,301
1,248 Added 1.75%
72,603 $21 Million
Q2 2022

Aug 12, 2022

BUY
$234.96 - $292.55 $44,877 - $55,877
191 Added 0.27%
71,355 $20.1 Million
Q1 2022

May 12, 2022

BUY
$221.42 - $260.97 $4.35 Million - $5.12 Million
19,627 Added 38.08%
71,164 $18.6 Million
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $3.61 Million - $4.56 Million
20,397 Added 65.5%
51,537 $11.3 Million
Q3 2021

Nov 05, 2021

BUY
$181.39 - $202.99 $276,438 - $309,356
1,524 Added 5.15%
31,140 $5.65 Million
Q2 2021

Aug 06, 2021

SELL
$187.49 - $221.1 $20,623 - $24,321
-110 Reduced 0.37%
29,616 $5.97 Million
Q1 2021

May 07, 2021

SELL
$207.02 - $241.31 $3.3 Million - $3.85 Million
-15,956 Reduced 34.93%
29,726 $6.39 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $370,340 - $493,925
-1,789 Reduced 3.77%
45,682 $10.8 Million
Q3 2020

Nov 06, 2020

BUY
$255.65 - $303.1 $402,648 - $477,382
1,575 Added 3.43%
47,471 $12.9 Million
Q2 2020

Aug 07, 2020

BUY
$225.48 - $295.8 $4.88 Million - $6.4 Million
21,649 Added 89.29%
45,896 $13.3 Million
Q1 2020

May 08, 2020

BUY
$199.77 - $247.81 $171,202 - $212,373
857 Added 3.66%
24,247 $5.77 Million
Q4 2019

Feb 07, 2020

BUY
$166.71 - $223.91 $5,501 - $7,389
33 Added 0.14%
23,390 $5.12 Million
Q3 2019

Nov 08, 2019

SELL
$166.23 - $187.09 $271,952 - $306,079
-1,636 Reduced 6.55%
23,357 $3.96 Million
Q2 2019

Aug 09, 2019

SELL
$164.61 - $190.37 $171,523 - $198,365
-1,042 Reduced 4.0%
24,993 $0
Q1 2019

May 10, 2019

BUY
$163.73 - $194.7 $196,476 - $233,640
1,200 Added 4.83%
26,035 $0
Q4 2018

Feb 08, 2019

SELL
$151.91 - $192.21 $1.05 Million - $1.33 Million
-6,915 Reduced 21.78%
24,835 $4.12 Million
Q3 2018

Nov 09, 2018

BUY
$167.73 - $192.74 $1.46 Million - $1.68 Million
8,707 Added 37.79%
31,750 $0
Q2 2018

Aug 10, 2018

SELL
$145.72 - $169.96 $265,939 - $310,177
-1,825 Reduced 7.34%
23,043 $0
Q1 2018

May 11, 2018

BUY
$151.6 - $177.13 $167,972 - $196,260
1,108 Added 4.66%
24,868 $0
Q4 2017

Feb 09, 2018

SELL
$137.28 - $155.55 $294,465 - $333,654
-2,145 Reduced 8.28%
23,760 $0
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $3.84 Million - $4.2 Million
25,905
25,905 $0

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.